Metformina + Vildagliptina

Metformin Hydrochloride, the active ingredient in Metformina + Vildagliptina, is a biguanide/DPP‑4 inhibitor presented as a tablet for oral use. It helps lower elevated blood glucose levels in adults diagnosed with type 2 diabetes mellitus by improving insulin sensitivity and enhancing insulin secretion.

GNH USA supplies Metformina + Vildagliptina as a licensed, GDP‑compliant product to hospitals, pharmacies and clinics worldwide, ensuring quality assurance and regulatory conformity for international markets through a robust supply chain and dedicated technical support.

Metformina + Vildagliptina is indicated for the management of type 2 diabetes mellitus, a chronic metabolic disorder characterized by insulin resistance and impaired insulin secretion.

- Type 2 diabetes mellitus: improves glycemic control in adults when combined therapy is required. - Inadequate response to metformin monotherapy: adds DPP‑4 inhibition to achieve additional glucose lowering. - Patients needing a fixed‑dose combination: simplifies regimen and may enhance adherence.

The combination may be associated with a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Nausea, abdominal discomfort, or dyspepsia: mild gastrointestinal upset that may improve with continued therapy. - Diarrhea: loose stools occurring intermittently, usually self‑limiting. - Headache: mild to moderate intensity, often transient.

Serious or Rare Side Effects: - Lactic acidosis: rare metabolic emergency characterized by elevated lactate, requiring immediate medical attention. - Severe hypoglycemia: pronounced low blood glucose, especially when used with insulin or sulfonylureas, presenting with confusion, sweating, or loss of consciousness. - Acute pancreatitis: inflammation of the pancreas presenting with severe abdominal pain, nausea, and elevated pancreatic enzymes.

When prescribing Metformina + Vildagliptina, clinicians should consider several precautionary measures to ensure safe use.

- Renal function: assess creatinine clearance before initiation and periodically, as metformin accumulation can increase lactic acidosis risk. - Hepatic impairment: use with caution in patients with liver disease due to altered drug metabolism. - Cardiovascular disease: monitor for heart failure, as metformin is contraindicated in unstable conditions. - Concomitant medications: review for drugs that may affect renal clearance or increase hypoglycemia risk. - Pregnancy and lactation: avoid use unless benefits outweigh potential risks, as safety data are limited. - Store at ambient temperature: keep below 25 °C in the original packaging, protect from moisture and direct sunlight.

Metformina + Vildagliptina may interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Insulin or sulfonylureas: increased risk of severe hypoglycemia. - Iodinated contrast agents: may precipitate renal impairment, requiring temporary discontinuation of metformin. - Cimetidine: can raise metformin plasma concentrations.

Moderate Interactions (Monitor Closely): - Diuretics (thiazides): may enhance hyperglycemic effect of metformin. - Corticosteroids: can reduce glucose‑lowering efficacy, necessitating dose adjustment. - Anticoagulants (e.g., warfarin): vildagliptin may affect INR, requiring monitoring.